Cooper Companies Inc (COO) Receives $276.22 Consensus PT from Analysts

Shares of Cooper Companies Inc (NYSE:COO) have been given a consensus recommendation of “Buy” by the twelve analysts that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $276.22.

A number of brokerages have issued reports on COO. Zacks Investment Research upgraded shares of Cooper Companies from a “sell” rating to a “hold” rating in a research note on Monday, October 1st. ValuEngine upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research note on Thursday, September 27th. Wells Fargo & Co upped their price target on shares of Cooper Companies from $290.00 to $295.00 and gave the company an “outperform” rating in a research note on Monday, November 12th. Raymond James upped their price target on shares of Cooper Companies from $270.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, September 21st. Finally, BMO Capital Markets upped their price target on shares of Cooper Companies from $280.00 to $285.00 and gave the company an “outperform” rating in a research note on Friday, August 31st.

NYSE COO opened at $278.83 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.58 and a quick ratio of 1.54. The company has a market cap of $13.70 billion, a P/E ratio of 28.75, a PEG ratio of 2.13 and a beta of 0.76. Cooper Companies has a 52 week low of $216.47 and a 52 week high of $281.75.

Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, August 30th. The medical device company reported $3.00 EPS for the quarter, missing the consensus estimate of $3.07 by ($0.07). The firm had revenue of $660.00 million for the quarter, compared to the consensus estimate of $653.44 million. Cooper Companies had a return on equity of 17.53% and a net margin of 5.23%. Research analysts forecast that Cooper Companies will post 11.61 earnings per share for the current fiscal year.

In other news, Director Robert S. Weiss sold 58,543 shares of the company’s stock in a transaction on Wednesday, September 5th. The shares were sold at an average price of $252.82, for a total value of $14,800,841.26. Following the sale, the director now directly owns 157,710 shares of the company’s stock, valued at approximately $39,872,242.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Agostino Ricupati sold 1,575 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $261.56, for a total transaction of $411,957.00. Following the completion of the sale, the senior vice president now directly owns 1,897 shares in the company, valued at $496,179.32. The disclosure for this sale can be found here. Insiders sold a total of 80,809 shares of company stock worth $20,740,667 over the last ninety days. Insiders own 1.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Cooper Companies by 0.6% during the third quarter. Vanguard Group Inc. now owns 5,041,468 shares of the medical device company’s stock worth $1,397,243,000 after buying an additional 31,280 shares in the last quarter. Morgan Stanley lifted its holdings in Cooper Companies by 734.7% during the third quarter. Morgan Stanley now owns 177,658 shares of the medical device company’s stock valued at $49,238,000 after purchasing an additional 156,373 shares in the last quarter. Legal & General Group Plc lifted its holdings in Cooper Companies by 9.7% during the third quarter. Legal & General Group Plc now owns 255,020 shares of the medical device company’s stock valued at $70,679,000 after purchasing an additional 22,461 shares in the last quarter. Sawgrass Asset Management LLC lifted its holdings in Cooper Companies by 29.5% during the third quarter. Sawgrass Asset Management LLC now owns 140,077 shares of the medical device company’s stock valued at $38,822,000 after purchasing an additional 31,880 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Cooper Companies by 31.3% during the third quarter. Nordea Investment Management AB now owns 2,562 shares of the medical device company’s stock valued at $709,000 after purchasing an additional 611 shares in the last quarter.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Read More: Institutional Investors

Analyst Recommendations for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit